ISSN: 1172-7047

Journal Home

Journal Guideline

CNS Drugs Q1 Unclaimed

Adis International Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

CNS Drugs is a journal indexed in SJR in Neurology (clinical) and Psychiatry and Mental Health with an H index of 129. It has a price of 3190 €. It has an SJR impact factor of 1,616 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,616.

CNS Drugs focuses its scope in these topics and keywords: comprehensive, review, receptorsefficacy, properties, peptide, patients, pathophysiology, orthostatic, neurogenic, reviewmanagement, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Neurology (clinical) (Q1) Pharmacology (medical) (Q1) Psychiatry and Mental Health (Q1)

Price

3190 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,616

SJR Impact factor

129

H Index

74

Total Docs (Last Year)

264

Total Docs (3 years)

5881

Total Refs

1631

Total Cites (3 years)

253

Citable Docs (3 years)

6.14

Cites/Doc (2 years)

79.47

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

The Lancet Neurology Q1
Neuro-Oncology Q1
Nature Reviews Neurology Q1
JAMA Neurology Q1
Molecular Neurodegeneration Q1

Compare this journals

Aims and Scope

Best articles by citations

A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females

Clinical Implications of CNS Penetration of Antiretroviral Drugs

Use of Atomoxetine in Patients with Attention-Deficit Hyperactivity Disorder and Co-Morbid Conditions

Neuropeptide and Sigma Receptors as Novel Therapeutic Targets for the Pharmacotherapy of Depression

FOREWORD

Comment on: "Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence"

Venous Thromboembolism in Recipients of Antipsychotics

Stimulation of the Nervous System for the Management of Seizures

Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis

Amyotrophic Lateral Sclerosis

Efficacy and Safety of Intravenous Valproate for Status Epilepticus: A Systematic Review

Treatment of Epilepsy in Women of Childbearing Potential

SHOW MORE ARTICLES

Eslicarbazepine Acetate

Discontinuation Syndrome Associated with Paroxetine in Depressed Patients

Emergency and Critical Care Management of Acute Ischaemic Stroke

Treatment of Partial Seizures in Childhood

New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability

Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis

Management of Psychiatric Comorbidity in Anorexia Nervosa and??Bulimia Nervosa

Pharmacotherapy for Cannabis Dependence

Mood Stabilizers and Antipsychotics for Acute Mania: A Systematic Review and Meta-Analysis of Combination/Augmentation Therapy Versus Monotherapy

Pregabalin in the Treatment of Generalised Anxiety Disorder

Weight Regain after Discontinuation of Topiramate Treatment in Patients with Migraine: a Prospective Observational Study

Prevention Studies in Alzheimer's Disease: Progress Towards the Development of New Therapeutics